Real-World Effectiveness of the Gla-300 + Cap + App Program in Adult Users Living with Type 2 Diabetes in Taiwan

IF 3.8 3区 医学 Q2 Medicine
Chih-Yuan Wang, Fang L. Zhou, Aakash B. Gandhi, Tsung-Ying Lee, Nancy Cui, Jiuo-Shan Mao, Jung-Fu Chen
{"title":"Real-World Effectiveness of the Gla-300 + Cap + App Program in Adult Users Living with Type 2 Diabetes in Taiwan","authors":"Chih-Yuan Wang, Fang L. Zhou, Aakash B. Gandhi, Tsung-Ying Lee, Nancy Cui, Jiuo-Shan Mao, Jung-Fu Chen","doi":"10.1007/s13300-024-01570-1","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Introduction</h3><p>Health2Sync (H2S) is a digital health technology platform that provides coaching and titration support to patients with diabetes. The Mallya cap converts a conventional insulin pen into a smart connected device that can automatically synchronize dose values and associated timestamps (upon injection) to the H2S platform. This single-arm real-world study evaluated the effectiveness of insulin glargine 300 U/mL (Gla-300) combined with H2S and Mallya cap (Gla-300 + Cap + App program) on clinical outcomes among users with type 2 diabetes (T2D) in Taiwan.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Adults (aged ≥ 20 years) with T2D who were registered H2S users and initiated Mallya cap for a new/existing Gla-300 regimen (identification period May 1, 2021–May 31, 2022) were included in this retrospective cohort study. Follow-up data from H2S were collected for 90 days. Glycated hemoglobin (HbA<sub>1c</sub>) change (baseline to follow-up) and HbA<sub>1c</sub> goal attainment were primary outcomes. Hypoglycemia incidence and usage metrics of Mallya cap were secondary outcomes.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Of 83 participants, 38.6% were new Gla-300 users. HbA<sub>1c</sub> was reduced in both new (− 2.4 [2.7] %, − 26.2 [29.5] mmol/mol) and previous Gla-300 users (− 0.5 [1.6] %, − 5.5 [17.5] mmol/mol). Reduction in HbA<sub>1c</sub> was significant (<i>p</i> &lt; 0.05) in both groups. At follow-up, 43.4% of users had a reduction of &gt; 0.5%. Mean HbA<sub>1c</sub> reductions increased numerically with higher baseline HbA<sub>1c</sub> and with longer duration of Mallya cap usage.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Use of digital technology within a connected ecosystem such as Gla-300 + Cap + App program could help people with type 2 diabetes to improve their glycemic condition.</p>","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":null,"pages":null},"PeriodicalIF":3.8000,"publicationDate":"2024-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13300-024-01570-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Health2Sync (H2S) is a digital health technology platform that provides coaching and titration support to patients with diabetes. The Mallya cap converts a conventional insulin pen into a smart connected device that can automatically synchronize dose values and associated timestamps (upon injection) to the H2S platform. This single-arm real-world study evaluated the effectiveness of insulin glargine 300 U/mL (Gla-300) combined with H2S and Mallya cap (Gla-300 + Cap + App program) on clinical outcomes among users with type 2 diabetes (T2D) in Taiwan.

Methods

Adults (aged ≥ 20 years) with T2D who were registered H2S users and initiated Mallya cap for a new/existing Gla-300 regimen (identification period May 1, 2021–May 31, 2022) were included in this retrospective cohort study. Follow-up data from H2S were collected for 90 days. Glycated hemoglobin (HbA1c) change (baseline to follow-up) and HbA1c goal attainment were primary outcomes. Hypoglycemia incidence and usage metrics of Mallya cap were secondary outcomes.

Results

Of 83 participants, 38.6% were new Gla-300 users. HbA1c was reduced in both new (− 2.4 [2.7] %, − 26.2 [29.5] mmol/mol) and previous Gla-300 users (− 0.5 [1.6] %, − 5.5 [17.5] mmol/mol). Reduction in HbA1c was significant (p < 0.05) in both groups. At follow-up, 43.4% of users had a reduction of > 0.5%. Mean HbA1c reductions increased numerically with higher baseline HbA1c and with longer duration of Mallya cap usage.

Conclusions

Use of digital technology within a connected ecosystem such as Gla-300 + Cap + App program could help people with type 2 diabetes to improve their glycemic condition.

Abstract Image

Gla-300 + Cap + App 计划对台湾 2 型糖尿病成人用户的实际效果
导言Health2Sync(H2S)是一个数字健康技术平台,为糖尿病患者提供指导和滴定支持。Mallya 笔帽可将传统的胰岛素笔转换为智能连接设备,可自动将剂量值和相关时间戳(注射时)同步到 H2S 平台。这项单臂真实世界研究评估了格列卫胰岛素 300 U/mL(Gla-300)与 H2S 和 Mallya cap(Gla-300 + Cap + App 程序)结合使用对台湾 2 型糖尿病(T2D)患者临床疗效的影响。方法这项回顾性队列研究纳入了注册为 H2S 用户并在新的/已有的 Gla-300 方案中使用 Mallya cap 的 T2D 成人(年龄≥ 20 岁)(识别期为 2021 年 5 月 1 日至 2022 年 5 月 31 日)。收集了 H2S 90 天的随访数据。糖化血红蛋白 (HbA1c) 变化(基线至随访)和 HbA1c 目标实现情况是主要结果。在 83 名参与者中,38.6% 是 Gla-300 的新用户。新用户(- 2.4 [2.7] %,- 26.2 [29.5] mmol/mol)和 Gla-300 老用户(- 0.5 [1.6] %,- 5.5 [17.5] mmol/mol)的 HbA1c 均有所降低。两组患者的 HbA1c 均有显著降低(p < 0.05)。在随访中,43.4% 的使用者的 HbA1c 下降了 0.5%。结论在 Gla-300 + Cap + App 程序等互联生态系统中使用数字技术可以帮助 2 型糖尿病患者改善血糖状况。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Diabetes Therapy
Diabetes Therapy Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
6.90
自引率
7.90%
发文量
130
审稿时长
6 weeks
期刊介绍: Diabetes Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all areas of diabetes. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Diabetes Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信